Precigen

GenVec, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focused on the development of innovative therapeutics and vaccines utilizing its proprietary AdenoVerse gene delivery platform. The company manufactures adenoviral-based product candidates, with its lead product, CGF166, currently undergoing Phase I/II clinical trials for the treatment of hearing loss and balance disorders. GenVec is also advancing vaccine candidates such as GV2311 for respiratory syncytial virus and GV2207 for herpes simplex virus. The company collaborates with Novartis for CGF166 and partners with other organizations, including TheraBiologics, the National Institute of Allergy and Infectious Diseases, and Merial, to develop solutions for various health challenges. Founded in 1992, GenVec addresses both human and animal health concerns, including malaria and foot-and-mouth disease prevention.

EnviroFlight, LLC is a producer of sustainable animal and plant nutrition products, established in 2009 and based in Maysville, Kentucky. The company specializes in processing waste distillers grains using black soldier fly larvae to create a range of nutrient-rich products, including EnviroBug, EnviroMeal, EnviroOil, and EnviroFrass. These products serve various markets, including poultry, aquaculture, pets, and zoo animals, and can also be utilized as fertilizers. EnviroFlight focuses on utilizing regionally available, low-value materials to drive positive change in the global food supply, while emphasizing the elimination of toxins, hormones, and antibiotics. As a subsidiary of Darling Ingredients Inc., EnviroFlight aims to enhance food supply sustainability while reducing environmental and financial costs associated with traditional nutrient production.

Oxitec Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative and environmentally friendly solutions for controlling insect pests that threaten global health and agriculture. Founded in 2002, the company utilizes proprietary technology derived from research at the University of Oxford, which incorporates genetics and molecular biology to enhance the effectiveness and safety of the Sterile Insect Technique (SIT). Oxitec offers a range of products, including genetically modified strains of Aedes aegypti and Aedes albopictus mosquitoes, as well as various agricultural pests such as the diamondback moth and pink bollworm. These products are designed to reduce pest populations in a targeted and sustainable manner, minimizing the impact on ecosystems and human health. Oxitec also operates a mosquito production facility in Piracicaba, Brazil, furthering its mission to combat diseases like dengue fever and protect crop yields.

ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of a new generation of biological drugs, utilizing a versatile and proprietary technology platform. This platform focuses on a delivery system that employs living non-pathogenic microorganisms for the oral administration of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, positioning itself at the forefront of innovative therapeutic solutions.

Histogenics Corporation, founded in 2000 and headquartered in Waltham, Massachusetts, is a regenerative medicine company specializing in the development and commercialization of therapeutic medical products for musculoskeletal conditions. The company's innovative platform integrates cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to address cartilage damage and improve joint function. Its primary investigational product, NeoCart, is a tissue implant designed to treat cartilage injuries in the knee, aiming to regenerate healthy cartilage and enhance overall joint performance. In 2019, Histogenics was acquired by Ocugen, Inc., marking a significant transition in its corporate structure.

MediStem, established in 2005, specializes in the development, acquisition, and commercialization of adult stem cell-based therapeutic products. The company holds 16 families of patent applications and has numerous scientific publications to its credit. It has also generated revenue through out-licensing certain technologies. Medistem's primary focus is on Endometrial Regenerative Cells (ERC), a type of universal donor pluripotent stem cell. ERCs are being developed to treat critical limb ischemia, an advanced form of peripheral artery disease, by promoting new blood vessel formation, reducing inflammation, regulating immune system function, and enhancing tissue repair and healing.

Immunologix, Inc. is a biotechnology company that specializes in the development and production of antibody-based therapeutics targeting a wide array of biological agents. Established in 2008 and located in Charleston, South Carolina, Immunologix focuses on creating human monoclonal antibodies against various pathogens, including viral and bacterial antigens, as well as tumor antigens and human autoantigens. The company employs innovative technology that converts naïve B-cells, sourced from tonsillectomies or whole blood collections, into fully mature human B-cells capable of producing specific human antibodies tailored to desired targets.

Agarigen is a North Carolina-based company that has developed a novel, mushroom-based expression platform for the rapid, high yield production of recombinant proteins.